{"entity":{"id":"mrg002","kind":"drug","name":"MRG002","aka":[],"tldr":"MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.","summary":"MRG002 is an investigational agent whose form is not stated in the registry developed by Shanghai Miracogen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05754853 (A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer), in gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer. The largest, NCT05754853, plans to enrol 290 participants with primary completion was scheduled for 2025-10 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of MRG002","url":"https://clinicaltrials.gov/search?intr=MRG002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shanghai-miracogen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05754853","nct04492488"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mrg002/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"company":[{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/"}],"trial":[{"id":"nct04492488","kind":"trial","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","route":"/trials/nct04492488/"},{"id":"nct05754853","kind":"trial","name":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","route":"/trials/nct05754853/"}]}}